digoxin
Modify Date: 2024-01-02 12:59:46
digoxin structure
|
Common Name | digoxin | ||
|---|---|---|---|---|
| CAS Number | 20830-75-5 | Molecular Weight | 780.938 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 931.6±65.0 °C at 760 mmHg | |
| Molecular Formula | C41H64O14 | Melting Point | 248-250ºC | |
| MSDS | Chinese USA | Flash Point | 278.5±27.8 °C | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
Use of digoxinDigoxin is a potent inhibitor of Na+/K+-ATPase, clinically used to treat arrhythmia and heart failure. |
| Name | digoxin |
|---|---|
| Synonym | More Synonyms |
| Description | Digoxin is a potent inhibitor of Na+/K+-ATPase, clinically used to treat arrhythmia and heart failure. |
|---|---|
| Related Catalog | |
| Target |
Na+/K+ ATPase[1] |
| In Vitro | Digoxin, a sodium-potassium ATPase inhibitor, has a negative Z score of −26.67, suggesting a function for the sodium-potassium ATPase in CHIKV infection. Relative to DMSO-treated cells, treatment of U-2 OS cells with Digoxin results in a dose-dependent decrease in CHIKV infection with a half-maximal effective concentration (EC50) of 48.8 nM. Digoxin treatment similarly decreases CHIKV infection of primary human synovial fibroblasts (HSFs) and Vero African green monkey kidney cells with EC50s of 43.9 nM and 67.3 nM, respectively. Digoxin treatment significantly diminishes CHIKV infection in these cell types, with EC50s of 16.2 µM in ST2 cells and 23.2 µM in C2C12 cells, values 330 and 475 times the EC50 of Digoxin in U-2 OS cells. Cell viability is only modestly impaired at 24 h posttreatment with 1 µM Digoxin, a dose 20 times the Digoxin EC50 for CHIKV antiviral activity in these cells[1]. |
| Cell Assay | U-2 OS cells seeded in 60-mm-diameter dishes are incubated with DMSO, 10 µM STS as an inducer of apoptosis, or increasing concentrations of Digoxin at 37°C for 6 h. Cells are washed with fluorescence-activated cell sorter (FACS) buffer (PBS with 2% FBS) and stained with PI. Cell staining is quantified using a BD LSRII flow cytometer and FlowJo software. Alternatively, U-2 OS cells seeded in 96-well plates are incubated with DMSO, STS, or increasing concentrations of Digoxin at 37°C for 6 or 24 h. PrestoBlue reagent is added to supernatants of compound-treated cells, and cells are incubated at 37°C for 30 min. Fluorescence as a surrogate for cell viability is quantified using a Synergy H1 plate reader[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 931.6±65.0 °C at 760 mmHg |
| Melting Point | 248-250ºC |
| Molecular Formula | C41H64O14 |
| Molecular Weight | 780.938 |
| Flash Point | 278.5±27.8 °C |
| Exact Mass | 780.429626 |
| PSA | 203.06000 |
| LogP | 0.85 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.602 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic; |
| Risk Phrases | R25 |
| Safety Phrases | S28-S45 |
| RIDADR | UN 3462 6 |
| WGK Germany | 3 |
| RTECS | IH6125000 |
| Packaging Group | II |
| Hazard Class | 6.1 |
|
~91%
digoxin CAS#:20830-75-5 |
| Literature: Lepojevic, Zika; Pekic, Branislav Carbohydrate Research, 1995 , vol. 271, # 1 p. 119 - 124 |
|
~%
digoxin CAS#:20830-75-5 |
| Literature: Pharmazie, , vol. 44, # 7 p. 508 |
|
~%
digoxin CAS#:20830-75-5 |
| Literature: Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321 |
|
~%
digoxin CAS#:20830-75-5 |
| Literature: Journal of the American Pharmaceutical Association (1912-1977), , vol. 41, p. 146,150 Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321 |
|
~%
digoxin CAS#:20830-75-5 |
| Literature: Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321 |
|
~%
digoxin CAS#:20830-75-5 |
| Literature: Steroids, , vol. 38, # 1 p. 11 - 28 |
![3-[(3S,5R,7S,8S,9S,10S,13R,17R)-3-[(2S,4S,5R,6R)-4,5-bis[[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy]-6-methyloxan-2-yl]oxy-7,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one structure](https://www.chemsrc.com/caspic/425/18810-27-0.png)
| Precursor 5 | |
|---|---|
| DownStream 6 | |
CAS#:1672-46-4
CAS#:5352-63-6
CAS#:5297-05-2|
Rapid detection of convallatoxin using five digoxin immunoassays.
Clin. Toxicol. (Phila.) 52(7) , 659-63, (2014) Cardiac glycosides of plant origin are implicated in toxic ingestions that may result in hospitalization and are potentially lethal. The utility of commonly available digoxin serum assays for detectin... |
|
|
Effects of intestinal microbiota on the bioavailability of geniposide in rats.
J. Agric. Food Chem. 62(40) , 9632-6, (2014) This study investigated the effects of intestinal microbiota on the metabolism of geniposide by using a rat model treated with a mixture of antibiotics. The plasma concentration of geniposide was dete... |
|
|
Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.
Biopharm. Drug Dispos. 35(5) , 253-63, (2014) An unusual, but clinically significant, digoxin (DIG)-bupropion (BUP) drug interaction (DDI), in which BUP increased DIG renal clearance by 80% is reported. To investigate the mechanism(s) of this unu... |
| Dixina |
| Digacin |
| Digonix |
| Cordioxil |
| Homolle's digitalin |
| Mapluxin |
| Lanocardin |
| card-20(22)-enolide, 3-[[O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3b,5b,12b)- |
| Lanacrist |
| 4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanon |
| Purgoxin |
| Longdigox |
| EINECS 244-068-1 |
| Digoxina-Sandoz |
| ROUGOXIN |
| Stillacor |
| NeoDioxanin |
| SK-Digoxin |
| Natigoxin |
| Davoxin |
| Digoxin Nativelle |
| Fargoxin |
| 4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]furan-2(5H)-on |
| Digos |
| Dimecip |
| Neo-Lanicor |
| digoxin |
| 12b-Hydroxydigitoxin |
| Digon |
| (3b,5b,12b)-3-{[2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide |
| card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β) |
| Lanacordin |
| Dynamos |
| Saroxin |
| Coragoxine |
| Dokim |
| Lenoxin |
| 4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]furan-2(5H)-one |
| LOE 908 hydrochloride |
| Grexin |
| Digoxin-Zori |
| 4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone |
| Cardiogoxin |
| Digossina |
| Cardigox |
| Hemigoxine Nativelle |
| (3β,5β,12β)-3-{[2,6-Dideoxy-β-D-ribo-hexopyranosyl-(1->;4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolid |
| 4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy |
| (3β,5β,12β)-3-{[2,6-Didésoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-didésoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-didésoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-ènolide |
| MFCD00003674 |
| Lanatilin |
| Digomal |
| Digosin |
| Lanoxin PG |
| Lanikor |
| Lanorale |
| Lanoxicaps |
| Toloxin |
| Lanoxin |
| (3b,5b,12b)-3-[(O-2,6-Dideoxy-b-D-ribo-hexopyranosyl-(1®4)-O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide |
| Cardioxin |
| card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)- |
| Lanicor |
| Card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)
 - |
| Novodigal-Amp. |
| Dilanacin |
| Vanoxin |
| [2H]-Digoxin |
| Lenoxicaps |
| Lifusin |
| (3β,5β,12β)-3-{[2,6-Dideoxy-β-D-ribo-hexopyranosyl-(1->;4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide |
| Eudigox |
| [14C]-Digoxin |